Fortrea account plan
Clinical development solutions
At a glance
Fortrea is a global contract research organization spun off from Labcorp, with $2,723.4 million of 2025 revenue and about 14,000 employees in 100 countries.
Fortrea is a contract research organization (CRO) providing phase I-IV clinical trial management, clinical pharmacology and consulting services to pharmaceutical, biotechnology and medical device customers, through Full Service, FSP and Hybrid models. It was spun off from Labcorp on June 30, 2023, trades on Nasdaq as FTRE and is headquartered in Durham, North Carolina, with about 14,000 employees working in approximately 100 countries. FY2025 revenues were $2,723.4 million (+1.0%), with a net loss of $(986.2) million driven by $797.9 million of goodwill impairment; backlog was $7.7 billion at December 31, 2025. Anshul Thakral is President and CEO.
Business units
Clinical Development
Fortrea's largest offering: full-service phase I-IV and real-world evidence studies, from protocol design and site start-up to data management, biostatistics and pharmacovigilance, delivered as Full Service, FSP or Hybrid. Oncology was 40% of 2025 full-service therapeutic-based revenue. Revenue fell in 2025 and 2026 on lower pass-through costs and lower FSP demand.
Clinical Pharmacology
First-in-human and early-phase studies with bioanalytics, pharmacokinetics and modelling, run from clinical research units in Leeds, Dallas, Daytona and Madison. It was the growth driver in 2025 and 2026, and the Worldwide Clinical Trials Early Phase Services deal takes Fortrea to more than 570 beds in the U.S. and U.K.
Consulting Services
Product development and regulatory strategy, market access, health economics and outcomes research and real-world evidence for small and large molecules, cell and gene therapies and biosimilars.
Strategic priorities
- Return to growth through the 3Rs
- The commercial strategy is "reach, relevance and repeat": Fortrea has been invited into large-pharma outsourcing refreshes it had not been part of before and won one, expected to convert into awards in 2028; biotech bookings grew almost double digits in 2026.
- Mid-teens adjusted EBITDA margin
- Management targets mid-teens margins in the next 3-5 years; the Q3 2026 adjusted EBITDA margin was 8.4%, up 120 basis points year on year.
- Grow clinical pharmacology
- The mix strategy is more clinical pharmacology, more FSO and less low-margin FSP, with a 300-bed Texas network and an in-house Austin bioanalytical lab added in October 2026.
- Fortrea Intelligent Technology
- FIT, launched in 2026, is an intelligence layer on the Xcellerate platform built module by module; the CRA mobile app is deployed in more than 49 countries and more than 95% of colleagues use AI weekly.
- China-linked biotech demand
- A new China leader was appointed in summer 2026 to grow with China-headquartered biotechs and multinationals running trials in China.
Latest results
In Q3 2026 Fortrea's revenues were $691.5 million, down 1.4% from $701.3 million, as lower clinical development pass-through costs and lower FSP demand offset growth in clinical pharmacology. GAAP net income was $0.6 million against a net loss of $(15.9) million, and adjusted EBITDA rose to $58.0 million from $50.7 million. Net business awards were $773 million for a book-to-bill of 1.12x; after a contract review, backlog was cut by $558 million to $7,316 million. FY2026 guidance was narrowed with higher midpoints: revenues of $2,665 million to $2,690 million and adjusted EBITDA of $210 million to $218 million.
Investments and deals
- Worldwide Clinical Trials Early Phase Services
- Acquired on October 19, 2026 for about $45.0 million, adding a 200-bed San Antonio clinic and an Austin bioanalytical laboratory; it is expected to be EBITDA-profitable in 2027.
- Debt reduction
- Fortrea repurchased $75.7 million of its 7.50% senior secured notes in Q4 2025; net leverage was 3.9x at Q3 2026, 1.4 turns lower in 12 months.
- Cost-savings programme
- The 2026 programme targets $70-80 million gross and $40-50 million net savings; restructuring charges were $44.1 million in 2025.
- Enabling Services divestment
- Fortrea sold its Enabling Services Segment (Fortrea Patient Access and Endpoint Clinical) for an adjusted price of $340.0 million, fully received in 2025.
Challenges and risks
- Customer concentration
- The largest customer was 17.6% of Q3 2026 revenue and the top 10 customers 53.5%; in 2025 one customer was approximately 18.1% of revenue.
- Revenue decline and backlog quality
- Nine-month 2026 revenues fell 2.7% to $2,006.2 million, and backlog was reduced by $558 million to reflect estimated scope and study delivery changes, including inactive trials.
- FSP pricing pressure
- FSP is very sticky but fairly low margin, and the CEO points to irrational pricing behavior by some larger players.
- Leverage and legacy losses
- Long-term debt was $1,048.0 million at end-2025 after a $(986.2) million net loss; a shareholder class action was filed in June 2025.
- Biotech funding and R&D budgets
- Risks include delayed or cancelled awards, biotech funding swings and R&D budget cuts, along with changes in U.S. policy and tariffs.
What leadership says
“Our sustained bookings momentum is building a foundation for growth.”
“our goal in AI is not automation for the sake of automation. It is to create a force multiplier for our people and our clients.”
“new management team, new strategy, flipping the chapter. It's not about spend, it's not about rightsizing, it's about growth.”
“So this is really about adding capabilities, not just capacity.”
Where a supplier can help
- Clinical pharmacology integration
- Tied to the Worldwide Clinical Trials acquisition and clinical pharmacology growth: lab equipment, LIMS, clinic operations and staffing for the San Antonio unit and the Austin bioanalytical lab.
- AI and clinical data platforms
- Tied to Fortrea Intelligent Technology: AI, analytics and workflow tools that plug into the Xcellerate data lake and the CRA mobile app, and integration with large pharma clients' own agentic solutions.
- Efficiency in support functions
- Tied to the cost-savings programme and the mid-teens margin target: outsourced support services and enterprise applications that let Fortrea scale without adding back capacity.
- Site activation and patient enrolment
- Tied to the operational priority on project management, site activation, enrolment and predictability: site selection, recruitment and trial technology vendors.
- Biotech and China market access
- Tied to biotech booking growth and the new China leader: partners that help reach U.S. and Chinese biotechs taking assets to the U.S. and Europe.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Fortrea?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Fortrea Holdings Inc. Annual Report on Form 10-K for the year ended December 31, 2025
- Fortrea is a global contract research organization (CRO), spun off from Labcorp on June 30, 2023, providing phase I-IV clinical trial management, clinical pharmacology and consulting services to pharmaceutical, biotechnology and medical device customers; about 14,300 employees operating in approximately 100 countries, headquartered in Durham, NC.
- FY2025 revenues were $2,723.4 million, up 1.0% (organic +0.8%); growth came from clinical pharmacology (including higher pass-through costs) while clinical development and functional service provider (FSP) revenue fell.
- Net loss was $(986.2) million, driven by $797.9 million of goodwill impairment in the Clinical Development reporting unit (taken at March 31 and June 30, 2025 after sustained share-price declines); segment operating income was $87.4 million vs $95.0 million in 2024.
- Backlog was $7.7 billion at December 31, 2025; one customer was approximately 18.1% of revenue, the top 10 customers about 57% and the top 20 about 69%; 56% of revenue came from leading pharmaceutical customers.
- Strategy rests on three pillars (commercial, operational and financial excellence): grow "reach, relevance and repeat business", lead with therapeutic expertise (oncology was 40% of full-service therapeutic-based revenue), build on clinical pharmacology, and invest selectively in AI, data and the Xcellerate platform.
- Cost actions continue: SG&A fell 18.6% to $456.4 million as Labcorp transition-services costs ended; restructuring charges were $44.1 million in 2025.
- Balance sheet: long-term debt of $1,048.0 million, cash of $174.6 million, $75.7 million of 7.50% notes repurchased in Q4 2025, undrawn $450.0 million revolver; operating cash flow fell to $113.5 million.
- Key risks: net new business awards and cancellations, customer concentration, biotech funding, backlog conversion, fixed-price overruns, debt covenants, and a shareholder class action filed in June 2025.
- Fortrea Holdings Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenues were $691.5 million, down 1.4% from $701.3 million (all organic); nine-month revenues were $2,006.2 million, down 2.7%.
- The decline came from lower clinical development revenue (mainly lower pass-through costs) and lower FSP demand, partly offset by growth in clinical pharmacology.
- Direct costs fell 4.6% to $552.0 million (79.8% of revenue vs 82.5%); SG&A fell 2.8% to $103.8 million thanks to restructuring savings and lower credit-loss provisions, partly offset by variable pay and merit increases.
- Q3 net income was $0.6 million (Q3 2025: net loss of $15.9 million); nine-month net loss was $(36.2) million vs $(953.7) million, which included the 2025 goodwill impairment.
- Backlog was $7.3 billion at September 30, 2026, after a reduction of approximately $558 million to reflect estimated changes in scope and study delivery requirements.
- On October 19, 2026 Fortrea bought the Early Phase Services division of Worldwide Clinical Trials for about $45.0 million.
- Liquidity: cash of $220.6 million, undrawn revolver ($447.7 million available), nine-month operating cash flow of $72.7 million vs $(15.6) million; variable-rate debt was $572.0 million.
- By geography, Q3 revenue was $326.0 million in North America, $222.2 million in Europe and $143.3 million elsewhere; Europe grew while North America and Other declined.
- Fortrea Reports Third Quarter 2026 Results (press release, Exhibit 99.1)
- Q3 2026 revenues were $691.5 million vs $701.3 million in Q3 2025.
- Book-to-bill was 1.12x for the quarter and 1.12x for the trailing 12 months.
- GAAP net income was $0.6 million ($0.01 per diluted share) vs a net loss of $(15.9) million; adjusted net income was $27.9 million ($0.28 per diluted share) vs $11.7 million.
- Adjusted EBITDA was $58.0 million vs $50.7 million; year-to-date adjusted EBITDA was $163.7 million vs $135.9 million.
- Operating cash flow was $60.8 million and free cash flow $52.5 million in the quarter.
- After a detailed contract review, backlog was cut by $558 million (including inactive trials) to $7,316 million; the company says this has no effect on 2026 guidance or near-term revenue estimates.
- FY2026 guidance narrowed with higher midpoints: revenue $2,665-2,690 million and adjusted EBITDA $210-218 million.
- CEO Anshul Thakral: "Our sustained bookings momentum is building a foundation for growth."
- Fortrea Q3 2026 earnings conference call (transcript)
- CEO Anshul Thakral presented Q3 as "another quarter of progress on our return to growth strategy": revenue of $691.5 million, adjusted EBITDA of $58 million, net business awards of $773 million and a book-to-bill of 1.12x.
- The Worldwide Clinical Trials Early Phase Services acquisition takes Fortrea to more than 570 beds in the U.S. and U.K., adds a 200-bed San Antonio clinic (a 300-bed Texas network with Dallas) and brings an Austin bioanalytical lab in-house; the first bioanalytical award came the day before the call.
- Commercial strategy is the "3Rs: reach, relevance and repeat". Fortrea was invited into large-pharma outsourcing refreshes it had not been part of before and has won one, expected to start converting into awards in 2028. Biotech bookings grew almost double digits in 2026, and a new China leader was appointed over the summer.
- On AI, Fortrea Intelligent Technology (FIT) is being built "module by module, workflow by workflow, persona by persona". The CRA mobile app is deployed in more than 49 countries, and more than 95% of colleagues use AI weekly through the Felix literacy programme.
- Margin target: mid-teens adjusted EBITDA margin remains the "true north". Q3 adjusted EBITDA margin was 8.4% (up 120 basis points year on year); compensation investments are a headwind of a couple of hundred basis points.
- CFO Jason Knoblauch: backlog cut by $558 million to $7.3 billion; net leverage 3.9x; net DSO 15 days; liquidity about $668 million; largest customer 17.6% of Q3 revenue, top 10 customers 53.5%.
- FY2026 guidance raised at the midpoint: revenue $2.665-2.690 billion and adjusted EBITDA $210-218 million. No 2027 guidance.
- Fortrea at the Baird 2026 Global Healthcare Conference (fireside chat transcript)
- CEO Anshul Thakral and CFO Jason Knoblauch (at his first public event) in a fireside chat with Baird analyst Eric Coldwell.
- Thakral framed the year as "flipping a page in the chapter of Fortrea": about 25%-30% of senior leaders are new, and the Worldwide Clinical Trials Early Phase Services deal is "symbolic" of the move from spin-off clean-up to running the strategy.
- The deal ends reliance on third parties for bioanalytical lab work and overflow beds: an Austin bioanalytical lab plus a 200-bed San Antonio unit that forms a 300-bed network with Dallas, opening up larger bioequivalence studies. Existing units are Leeds, Madison, Daytona Beach and Dallas.
- Target: "mid-teens margins in the next 3-5 years". Operating leverage becomes "very apparent" at mid-single-digit service-fee growth.
- Mix strategy: "more clinical pharmacology, more FSO, less low margin FSP". FSP is "very sticky but fairly low margin".
- Demand: the pipeline has risen every quarter for four quarters, decisions are timely and "pricing is rational"; Fortrea is competing in "half a dozen to a dozen" top-30 pharma partnership refreshes it was never invited to before.
- AI: no contracting or pricing changes yet ("at least a year away"); FIT is an intelligence layer on the Xcellerate data lake, rolled out persona by persona.
- Fortrea at the Jefferies Global Healthcare Conference 2026 (fireside chat transcript)
- CEO Anshul Thakral and then-CFO Jill McConnell in a fireside chat with Jefferies analyst David Windley, after three quarters in a row with book-to-bill above 1.1.
- Demand "has gotten better": large-pharma RFPs have restarted, biotech recovery is faster, FSO demand is returning after the price-driven FSP shift of 2024-2025, and clinical pharmacology demand is returning "even faster".
- McConnell: the guided 2026 revenue decline (about 4.5%, per the analyst) is mostly lower pass-through revenue; underlying service-fee revenue is trending toward flat by year-end, with "no hockey stick". The cost-savings programme targets $70-80 million gross and $40-50 million net.
- Concentration: the largest client is a 14-year partnership with "thousands of people" working on it, and its share should fall as Fortrea grows elsewhere. In one FSP renewal Fortrea accepted a price cut but refused more volume at a lower price, and "ended up being the highest price of the CROs that they kept".
- Sales was rebuilt across commercial, operations, customer-facing finance and legal; leaders' bonuses include net bookings; customers say Fortrea is "a lot easier to work with".
- AI: clients talk about it in every meeting, but meaningful workflow change is "a multi-year journey"; investor conversations run with "a three or four year lag" behind customer reality.
Questions about Fortrea
What does Fortrea do?
Fortrea is a contract research organization running phase I-IV clinical trials, clinical pharmacology studies and consulting for pharmaceutical, biotechnology and medical device companies, through full service, FSP and hybrid models.
What is Fortrea's revenue?
Fortrea's FY2025 revenues were $2,723.4 million, up 1.0%. For 2026 it guides to revenues of $2,665 million to $2,690 million.
How many employees does Fortrea have?
Fortrea had about 14,300 employees at the end of 2025 and now cites about 14,000 employees in approximately 100 countries.
What is Fortrea's strategy?
Fortrea's return-to-growth strategy rests on commercial, operational and financial excellence: winning more large pharma and biotech work, growing clinical pharmacology, building AI into Fortrea Intelligent Technology and reaching mid-teens adjusted EBITDA margins.
Who leads Fortrea?
Anshul Thakral is President and CEO, and Jason Knoblauch is Chief Financial Officer.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)